PLEASANTON, Calif.,
May 17, 2021 /PRNewswire/
-- Veeva Systems (NYSE: VEEV) today announced a
strategic partnership with Oncopeptides to support the launch of
the global biotech's first commercial product. Using Veeva
Link for real-time customer intelligence, Oncopeptides
recently launched PEPAXTO® (melphalan flufenamide), the first
anticancer peptide-drug conjugate approved by the U.S. Food and
Drug Administration (FDA) for multiple myeloma.
"Engaging the right healthcare providers (HCPs) is key in
determining how fast we can reach patients battling
difficult-to-treat hematological diseases," said Mohamed H. Ladha, general manager of the U.S.
business unit at Oncopeptides. "Veeva Link has given our medical
and commercial teams the strategic insights they need to accelerate
our launch and make meaningful connections from day one and
beyond."
Oncopeptides used Veeva Link to quickly identify top scientific
and clinical experts during pre-commercial planning, better engage
with them, and uncover key market-level insights. Veeva Link's
in-depth oncology expert profiles inform more value-driven field
interactions—both in the critical early days of a launch and
throughout ongoing commercialization activities. This supports the
company's field force territory planning, key opinion leader (KOL)
mapping, target account profiling, and speaker bureau
selection.
The biotech also benefits from Veeva's full suite of Commercial
Cloud applications, including solutions for multichannel
engagement, commercial content, and customer data. These
capabilities deliver data-driven insights and
facilitate smarter, compliant HCP interactions across all
channels.
"We're proud to partner with Oncopeptides to help bring this
important therapy to the market," said Kilian Weiss, general manager for Veeva Link at
Veeva Systems. "The company's dynamic field force is taking a
digital-first approach to customer engagement—helping accelerate
commercial success and support long-term, agile relationships—even
as HCP preferences and access continue to evolve."
Used by five of the ten largest pharmaceutical companies, Veeva
Link speeds market readiness for new life sciences products. It
provides fully compliant, real-time profiles on tens of thousands
of scientific experts and millions of activities in a single
enterprise view. With this strategic visibility, sales, marketing,
and medical teams gain deeper market insights, grow relationships,
and add value to customer interactions.
For more information on how Oncopeptides used these market-level
insights to accelerate its launch, register for the upcoming Veeva
Commercial & Medical North America Summit Connect on
June 10, 2021. The live one-day
virtual event is open to life sciences industry professionals.
Additional Information
For more on Veeva Link, visit:
veeva.com/veeva-link
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
About Oncopeptides
Oncopeptides is a global biotech company committed to developing
targeted therapies for patients facing hard-to-treat hematological
diseases. Oncopeptides has one U.S. FDA approved product,
PEPAXTO® (melphalan flufenamide), known during clinical
development as melflufen. PEPAXTO is approved for some patients
with triple-class refractory multiple myeloma and was evaluated in
several clinical studies including the pivotal Phase 2 HORIZON
study and is currently being evaluated in the confirmatory Phase 3
OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden, with a U.S. headquarters in
Boston, Massachusetts. In addition
to Boston, Oncopeptides has a
footprint in San Francisco,
California, another U.S. biotech hub. For more information,
please visit our corporate website at
https://oncopeptides.se/en/. You may also visit our U.S.
website at https://www.oncopeptides-us.com/en and follow us on
our U.S. social media channels, Twitter and LinkedIn.
PEPAXTO® is a trademark of Oncopeptides AB (publ).
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer
success, Veeva serves more than 975 customers, ranging
from the world's largest pharmaceutical companies to emerging
biotechs. As a Public Benefit Corporation, Veeva is committed to
balancing the interests of all stakeholders, including
customers, employees, shareholders, and the industries
it serves. For more information,
visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva's products and services,
the results from use of Veeva's products and services, and general
business conditions (including the on-going impact of COVID-19),
particularly within the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva's
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva's expectations as of the date of this
press announcement. Subsequent events may cause these expectations
to change, and Veeva disclaims any obligation to update the
forward-looking statements in the future. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional
risks and uncertainties that could affect Veeva's financial results
are included under the captions, "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations," in the company's filing on Form 10-K for the period
ended January 31, 2021. This is available on the
company's website at veeva.com under the Investors
section and on the SEC's website at sec.gov. Further
information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from
time to time.
Meagan Busath
Veeva Systems
925-452-6500
meagan.busath@veeva.com
|
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncopeptides-partners-with-veeva-to-drive-more-effective-engagement-ahead-of-first-commercial-launch-301292122.html
SOURCE Veeva Systems